- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ML-007C-MA
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 55 Years to 91 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Anaheim, California • Doral, Florida • Miami, Florida + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autism Spectrum Disorder
- Interventions
- ML-004 (IR)/(ER) tablet
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 12 Years to 46 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 18
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Glendale, California + 15 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- ML-004 (IR)/(ER) tablet, ML-004 Placebo
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 24
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Glendale, California + 21 more
- Conditions
- Schizophrenia
- Interventions
- ML-007C-MA
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 45
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 39 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ML-007C-MA, Placebo
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
- Conditions
- Schizophrenia
- Interventions
- Placebo, ML-007C-MA BID, ML-007C-MA QD
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Bellflower, California • Culver City, California + 21 more